Meeting the Costs of HIV Care
The Latest

This Week in HIV Research: Teamwork Makes the Dream Work
Dec. 28, 2020: The power of clinic-pharmacy collaborations; overcoming COVID-19-induced barriers to HIV care; urine testing as a PrEP adherence tool; using incarceration history in PrEP Rx assessments.

This Week in HIV Research: Are Our Priorities in the Right Place?
Dec. 10, 2020: Where the Ending the HIV Epidemic plan falls short; housing instability and HIV care incentives; financial wellbeing vs. health care access; San Diego's complex webs of HIV transmission.

HIV Incidence Is Lower in States With More Generous Low-Income Food Benefits
“The message that needs to be communicated to people in power, and it needs to be communicated loud and frequently, is, ‘Look. Here’s the actual human cost of not enacting these kinds of policies. Here’s the potential benefit,’” says Aaron Richterman, M.D., M.P.H.

Will the Biden-Harris Administration Breathe Life Back Into Vital HIV and Hepatitis Programs?
We spoke with Amy Killelea at NASTAD, a major national health policy advocacy organization, about the priorities she sees in January 2021 and beyond.

Three Immediate Ways the Fight Against HIV Is Likely to Change in the Biden-Harris Administration
Hopes rest on president-elect Biden to fight HIV along with COVID-19, implement a more humane and inclusive approach to health policy, and expand the Affordable Care Act.

This Week in HIV Research: Disclosing Our Disparities
Sept. 17, 2020: HIV prevalence gaps between Latinx people and non-Latinx white people; Obamacare awareness and perceptions among HIV clinicians; the relationship between pain and HIV; cancer mortality trends among PLWH.

This Week in HIV Research: PrEP So White
May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.

Why All HIV Care Must Be Trauma-Informed Care
Giving good HIV care means taking into account the many marginalize identities patients can hold. And, being marginalized often comes with a lot of trauma.

This Week in HIV Research: The Frustrating Relativity of Efficacy
March 26, 2020: Lopinavir/ritonavir falls short against COVID-19; impact of PrEP scale-up on HIV diagnoses; long-term cost-effectiveness of various HIV interventions; disparities in virologic suppression among young people.

Here’s How HIV Service Agencies Nationwide Are Adapting to the Coronavirus Crisis
Replacing group meetings and public outreach with telehealth consults, Zoom meet-ups, and food/med curbside deliveries are all part of the solutions.